Can we unlock the potential of IGF-1R inhibition in cancer therapy?

Cancer Treatment Reviews

Volumn 40, Issue 9, 2014, Pages 1096-1105

  King, Helen ^a   Aleksic, Tamara ^b   Haluska, Paul ^c   Macaulay, Valentine M ^b,d  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c Mayo Clinic   (United States)

^d CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

IGF; IGF 1R cancer therapy; Predictive biomarker; Therapeutic antibody; Type 1 IGF receptor; Tyrosine kinase inhibitor

Indexed keywords

1 [4 [(5 CYCLOPROPYL 1H PYRAZOL 3 YL)AMINO]PYRROLO[2,1 F][1,2,4]TRIAZIN 2 YL] N (6 FLUORO 3 PYRIDINYL) 2 METHYL 2 PYRROLIDINECARBOXAMIDE; ANTIBODY; ANTINEOPLASTIC AGENT; BI 836845; CARBOPLATIN; CIXUTUMUMAB; ERLOTINIB; EXEMESTANE; FIGITUMUMAB; GANITUMAB; GEMCITABINE; INSULIN LIKE GROWTH FACTOR 1 RECEPTOR ANTIBODY; INSULIN LIKE GROWTH FACTOR 1 RECEPTOR INHIBITOR; LETROZOLE; LIGAND ANTIBODY; LINSITINIB; PACLITAXEL; PANITUMUMAB; PHOSPHOTRANSFERASE INHIBITOR; RAPAMYCIN; RECEPTOR ANTIBODY; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY; PROTEIN KINASE INHIBITOR; TUMOR MARKER;

BREAST CANCER; CANCER SURVIVAL; COLORECTAL CANCER; DISEASE ASSOCIATION; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; DRUG TARGETING; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR DYNAMICS; NON SMALL CELL LUNG CANCER; NONHUMAN; OVERALL SURVIVAL; PANCREAS CANCER; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEIN DETERMINATION; PROTEIN FUNCTION; REVIEW; SARCOMA; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; SURVIVAL RATE; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); IMMUNOLOGY; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PROCEDURES;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROTEIN KINASE INHIBITORS; RECEPTOR, IGF TYPE 1; TUMOR MARKERS, BIOLOGICAL;

EID: 84928758281     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2014.07.004     Document Type: Review

References (178)

1. Yuen J.S., Macaulay V.M. Targeting the type 1 insulin-like growth factor receptor as a treatment for cancer. Expert Opin Ther Targets 2008, 12:589-603.
2. Gualberto A., Pollak M. Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Oncogene 2009, 28:3009-3021.
3. Tognon C.E., Sorensen P.H. Targeting the insulin-like growth factor 1 receptor (IGF1R) signaling pathway for cancer therapy. Expert Opin Ther Targets 2012, 16:33-48.
4. Sell C., Dumenil G., Deveaud C., et al. Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts. Mol Cell Biol 1994, 14:3604-3612.
5. Guevara-Aguirre J., Balasubramanian P., Guevara-Aguirre M., et al. Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. Sci Transl Med 2011, 3:70ra13.
6. Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer 2012, 12:159-169.
7. Dunn S.E., Ehrlich M., Sharp N.J., et al. A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer. Cancer Res 1998, 58:3353-3361.
8. Scotlandi K., Avnet S., Benini S., et al. Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing's sarcoma cells. Int J Cancer 2002, 101:11-16.
9. Lee H.Y., Chun K.H., Liu B., et al. Insulin-like growth factor binding protein-3 inhibits the growth of non-small cell lung cancer. Cancer Res 2002, 62:3530-3537.
10. Rochester M.A., Riedemann J., Hellawell G.O., et al. Silencing of the IGF1R gene enhances sensitivity to DNA-damaging agents in both PTEN wild-type and mutant human prostate cancer. Cancer Gene Ther 2005, 12:90-100.
11. Harper J., Burns J.L., Foulstone E.J., et al. Soluble IGF2 receptor rescues Apc(Min/+) intestinal adenoma progression induced by Igf2 loss of imprinting. Cancer Res 2006, 66:1940-1948.
12. Maloney E.K., McLaughlin J.L., Dagdigian N.E., et al. An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res 2003, 63:5073-5083.
13. Burtrum D., Zhu Z., Lu D., et al. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res 2003, 63:8912-8921.
14. Sachdev D., Li S.L., Hartell J.S., et al. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I. Cancer Res 2003, 63:627-635.
15. Mitsiades C.S., Mitsiades N.S., McMullan C.J., et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 2004, 5:221-230.
16. Garcia-Echeverria C., Pearson M.A., Marti A., et al. In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 2004, 5:231-239.
17. Cohen B.D., Baker D.A., Soderstrom C., et al. Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res 2005, 11:2063-2073.
18. Ji Q.S., Mulvihill M.J., Rosenfeld-Franklin M., et al. A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo. Mol Cancer Ther 2007, 6:2158-2167.
19. Rowinsky E.K., Youssoufian H., Tonra J.R., et al. IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Clin Cancer Res 2007, 13:5549s-5555s.
20. Carboni J.M., Wittman M., Yang Z., et al. BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR. Mol Cancer Ther 2009, 8:3341-3349.
21. Adam P.F., Hofmann M.H., Bogenrieder T., Borges E., Adolf G.R. BI 836845 a fully human IGF ligand neutralizing antibody, to improve the efficacy of rapamycin by blocking rapamycin-induced AKT activation. J Clin Oncol 2012, 30. [suppl.; abstr. 3092].
22. Haluska P., Menefee M.E., Plimack E.R., Rosenberg J.E., Northfelt D.W., LaVallee T., et al. Safety, pharmacokinetics and antitumor activity of MEDI-573, an investigational monoclonal antibody that targets IGF-I and IGF-II, in adult patients with advanced solid tumors. J Clin Oncol 2012, 30. [suppl.; abstr. TPS2618].
23. Sachdev D., Singh R., Fujita-Yamaguchi Y., et al. Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: implications for anti-insulin-like growth factor therapy in breast cancer. Cancer Res 2006, 66:2391-2402.
24. Wood E.R., Shewchuk L., Hassel A., et al. Discovery of an inhibitor of insulin-like growth factor 1 receptor activation: implications for cellular potency and selectivity over insulin receptor. Biochem Pharmacol 2009, 78:1438-1447.
25. Favelyukis S., Till J.H., Hubbard S.R., et al. Structure and autoregulation of the insulin-like growth factor 1 receptor kinase. Nat Struct Biol 2001, 8:1058-1063.
26. Yee D. Insulin-like growth factor receptor inhibitors: baby or the bathwater?. J Natl Cancer Inst 2012, 104:975-981.
27. Steiner L., Blum G., Friedmann Y., et al. ATP non-competitive IGF-1 receptor kinase inhibitors as lead anti-neoplastic and anti-papilloma agents. Eur J Pharmacol 2007, 562:1-11.
28. Ekman S., Frodin J.E., Harmenberg J., et al. Clinical Phase I study with an Insulin-like growth factor-1 receptor inhibitor: experiences in patients with squamous non-small cell lung carcinoma. Acta Oncol 2011, 50:441-447.
29. Friedbichler K., Hofmann M.H., Kroez M., et al. Pharmacodynamic and antineoplastic activity of BI 836845, a fully human IGF ligand neutralizing antibody, and mechanistic rationale for combination with rapamycin. Mol Cancer Ther 2013, 13:399-409.
30. Hartog H., Wesseling J., Boezen H.M., et al. The insulin-like growth factor 1 receptor in cancer: old focus, new future. Eur J Cancer 2007, 43:1895-1904.
31. Macaulay V.M. Insulin-like growth factors and cancer. Br J Cancer 1992, 65:311-320.
32. Tolcher A.W., Sarantopoulos J., Patnaik A., et al. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol 2009, 27:5800-5807.
33. Karp D.D., Pollak M.N., Cohen R.B., et al. Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatin. J Thorac Oncol 2009, 4:1397-1403.
34. Carden C.P., Kim E.S., Jones R.L., Alam S.M., Johnson F.M., Stephens A.W., et al. Phase I study of intermittent dosing of OSI-906, a dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in patients with advanced solid tumors. J Clin Oncol 2010, 28. [suppl.; abstr. 2530].
35. Haluska P., Shaw H.M., Batzel G.N., et al. Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res 2007, 13:5834-5840.
36. Higano C., Alumkal J., Ryan C.J., et al. A phase II study evaluating the efficacy and safety of single agent IMC A12, a monoclonal antibody (MAb), against the insulin-like growth factor-1 receptor (IGF-IR), as monotherapy in patients with metastastic, asymptomatic castration-resistant prostate cancer (CRPC). J Clin Oncol 2009, 27:15s. [suppl.; abstr. 5142].
37. Soria J.C., Massard C., Lazar V., et al. A dose finding, safety and pharmacokinetic study of AVE1642, an anti-insulin-like growth factor-1 receptor (IGF-1R/CD221) monoclonal antibody, administered as a single agent and in combination with docetaxel in patients with advanced solid tumours. Eur J Cancer 2013, 49:1799-1807.
38. Garcia J.A., Elson P., Cooney M.M., et al. Inhibition of the IGF pathway in metastatic castrate resistant prostate cancer (CRPC): results from a phase II study of OSI-906 (linsitinib). J Clin Oncol 2013, 31. [suppl.; abstr. e16022].
39. Olmos D., Postel-Vinay S., Molife L.R., et al. Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet Oncol 2010, 11:129-135.
40. Kurzrock R., Patnaik A., Aisner J., et al. A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors. Clin Cancer Res 2010, 16:2458-2465.
41. Tap W.D., Demetri G., Barnette P., et al. Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors. J Clin Oncol 2012, 30:1849-1856.
42. Reidy-Lagunes D.L., Vakiani E., Segal M.F., et al. A phase 2 study of the insulin-like growth factor-1 receptor inhibitor MK-0646 in patients with metastatic, well-differentiated neuroendocrine tumors. Cancer 2012, 118:4795-4800.
43. Schoffski P., Adkins D., Blay J.Y., et al. An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours. Eur J Cancer 2013, 49:3219-3228.
44. Weigel B., Malempati S., Reid J.M., et al. Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children's Oncology Group. Pediatr Blood Cancer 2013, 61:452-456. [epub Aug 17].
45. Ray-Coquard I., Haluska P., O'Reilly S., et al. A multicenter open-label phase II study of the efficacy and safety of ganitumab (AMG 479), a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R) as second-line therapy in patients with recurrent platinum-sensitive ovarian cancer. J Clin Oncol 2013, 31. [suppl.; abstr. 5515].
46. Rajan A., Carter C.A., Berman A., et al. Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial. Lancet Oncol 2014, 15:191-200.
47. Toretsky J.A., Kalebic T., Blakesley V., et al. The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts. J Biol Chem 1997, 272:30822-30827.
48. Ayalon D., Glaser T., Werner H. Transcriptional regulation of IGF-I receptor gene expression by the PAX3-FKHR oncoprotein. Growth Horm IGF Res 2001, 11:289-297.
49. Martin M.J., Melnyk N., Pollard M., et al. The insulin-like growth factor I receptor is required for akt activation and suppression of anoikis in cells transformed by the ETV6-NTRK3 chimeric tyrosine kinase. Mol Cell Biol 2006, 26:1754-1769.
50. Huang H.J., Angelo L.S., Rodon J., et al. R1507, an anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, and EWS/FLI-1 siRNA in Ewing's sarcoma: convergence at the IGF/IGFR/Akt axis. PLoS One 2011, 6:e26060.
51. Ekman S., Harmenberg J., Frödin J.-E., et al. A novel targeted oral insulin-like growth factor-1 receptor (IGF-1R) inhibitor and its implications for patients with non-small cell lung cancer (NSCLC): a phase I clinical trial. J Clin Oncol 2013, 30. [suppl.; abstr. 7539].
52. Cao L., Yu Y., Darko I., et al. Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody. Cancer Res 2008, 68:8039-8048.
53. Ferte C., Loriot Y., Clemenson C., et al. IGF-1R targeting increases the antitumor effects of DNA damaging agents in SCLC model: an opportunity to increase the efficacy of standard therapy. Mol Cancer Ther 2013, 12:1213-1222.
54. Fleuren E.D., Versleijen-Jonkers Y.M., van de Luijtgaarden A.C., et al. Predicting IGF-1R therapy response in bone sarcomas: immuno-SPECT imaging with radiolabeled R1507. Clin Cancer Res 2011, 17:7693-7703.
55. Chakravarti A., Loeffler J.S., Dyson N.J. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 2002, 62:200-207.
56. Hopkins A., Crowe P.J., Yang J.L. Effect of type 1 insulin-like growth factor receptor targeted therapy on chemotherapy in human cancer and the mechanisms involved. J Cancer Res Clin Oncol 2010, 136:639-650.
57. Chakraborty A.K., Welsh A., Digiovanna M.P. Co-targeting the insulin-like growth factor I receptor enhances growth-inhibitory and pro-apoptotic effects of anti-estrogens in human breast cancer cell lines. Breast Cancer Res Treat 2010, 120:327-335.
58. Cortot A.B., Repellin C.E., Shimamura T., et al. Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway. Cancer Res 2013, 73:834-843.
59. Karp D.D., Paz-Ares L.G., Novello S., et al. Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol 2009, 27:2516-2522.
60. Javale M.M., Varadhachary G.R., Fogelman D.R., Shroff R.T., Overman M.J., Ukegbu L., et al. Randomized phase II study of gemciabine (G) plus anti-IGF-1R antibody MK-0646, G plus erlotinib (E) plus MK-0646 and G plus E for advanced pancreatic cancer. J Clin Oncol 2011, 29. [suppl.; abstr. 4026].
61. Macaulay V.M., Middleton M.R., Eckhardt S.G., et al. Phase I study of OSI-906, dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in combination with erlotinib (E) in patients with advanced solid tumors. J Clin Oncol 2011, 29. [suppl.; abstr. 3098].
62. Reidy D.L., Vakiani E., Fakih M.G., et al. Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer. J Clin Oncol 2010, 28:4240-4246.
63. Weickhardt A., Doebele R., Oton A., et al. A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer. J Thorac Oncol 2012, 7:419-426.
64. Watkins D., Tabernero J., Schmoll H., et al. A randomized phase II/III study of the anti-IGF-1R antibody MK-0646 (dalotuzumab) in combination with cetuximab (Cx) and irinotecan (lr) in the treatment of chemofractory metastatic colorectal cancer (mCRC) with wild-type (wt) KRAS status. J Clin Oncol 2011, 29. [suppl.; abstr. 3501].
65. Watkins D.J., Ayers M., Cunningham D., Tabermero J., Telpar S., Kim T.-Y., Kim T.W., et al. Molecular analysis of the randomized phase II/III study of the anti-IGF-1R antibody dalotuzumab (MK-0646) in combination with cetuximab (Cx) and irinotecan (Ir) in the treatment of chemorefractory KRAS wild-type metastatic colorectal cancer (mCRC). J Clin Oncol 2012, 30. [suppl.; abstr. 3531].
66. Haluska P., Dhar A., Hou X., Huang F., Nuyten D.S.A., Park J. Phase II trial of the dual IGF-1R/IR inhibitor BMS-754807 with or without letrozole in aromatase inhibitor-resistant breast cancer. J Clin Oncol 2011, 29. [suppl.; abstr. TPS111].
67. Philip P.A., Goldman B., Ramanathan R.K., Lenz H.-J., Lowy A.M., Whitehead R.P., et al. Dual blockade of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor-1 (IGF-1R) signaling in metastatic pancreatic cancer: phase I/randomized II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG-0727). J Clin Oncol 2012, 3. [suppl.; abstr. 4019].
68. Awasthi N., Zhang C., Ruan W., et al. BMS-754807, a small-molecule inhibitor of insulin-like growth factor-1 receptor/insulin receptor, enhances gemcitabine response in pancreatic cancer. Mol Cancer Ther 2012, 11:2644-2653.
69. Matsumoto F., Valdecanas D.N., Mason K.A., et al. The impact of timing of EGFR and IGF-1R inhibition for sensitizing head and neck cancer to radiation. Anticancer Res 2012, 32:3029-3035.
70. Naing A., LoRusso P., Fu S., et al. Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors. Clin Cancer Res 2012, 18:2625-2631.
71. Macaulay V.M., Middleton M.R., Protheroe A.S., et al. Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors. Ann Oncol 2013, 24:784-791.
72. Schwartz G.K., Tap W.D., Qin L.X., et al. Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. Lancet Oncol 2013, 14:371-382.
73. Van Cutsem E., Eng C., Nowara E., et al. Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer. Clin Cancer Res 2014, 4. [epub June 11].
74. Doi T., Muro K., Yoshino T., et al. Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancer. Cancer Chemother Pharmacol 2013, 72:643-652.
75. Mahadevan D., Sutton G.R., Arteta-Bulos R., et al. Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies. Cancer Chemother Pharmacol 2014, 73:467-473.
76. Guha M. Anticancer IGF1R classes take more knocks. Nat Rev Drug Discov 2013, 12:250.
77. Thatcher N., Chang A., Parikh P., et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (iressa survival evaluation in lung cancer). Lancet 2005, 366:1527-1537.
78. Craddock B.P., Miller W.T. Effects of somatic mutations in the C-terminus of insulin-like growth factor 1 receptor on activity and signaling. J Signal Transduct 2012, 2012:804801.
79. Gualberto A., Hixon M.L., Karp D.D., et al. Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab. Br J Cancer 2011, 104:68-74.
80. Goto Y., Sekine I., Tanioka M., et al. Figitumumab combined with carboplatin and paclitaxel in treatment-naive Japanese patients with advanced non-small cell lung cancer. Invest New Drugs 2012, 30:1548-1556.
81. Ramalingam S.S., Spigel D.R., Chen D., et al. Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer. J Clin Oncol 2011, 29:4574-4580.
82. McCaffery I., Tudor Y., Deng H., et al. Putative predictive biomarkers of survival in patients with metastatic pancreatic adenocarcinoma treated with gemcitabine and ganitumab, an IGF1R inhibitor. Clin Cancer Res 2013, 19:4282-4289.
83. Clemmons D.R. Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer. Nat Rev Drug Discov 2007, 6:821-833.
84. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008, 8:915-928.
85. Gualberto A., Hixon M.L., Karp D.D., et al. Retraction of: pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab. Br J Cancer 2012, 107:2024.
86. Pavlicek A., Lira M.E., Lee N.V., et al. Molecular predictors of sensitivity to the insulin-like growth factor 1 receptor inhibitor, figitumumab (CP-751,871). Mol Cancer Ther 2013, 12:2929-2939.
87. Zha J., O'Brien C., Savage H., et al. Molecular predictors of response to a humanized anti-insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer. Mol Cancer Ther 2009, 8:2110-2121.
88. Mukohara T., Shimada H., Ogasawara N., et al. Sensitivity of breast cancer cell lines to the novel insulin-like growth factor-1 receptor (IGF-1R) inhibitor NVP-AEW541 is dependent on the level of IRS-1 expression. Cancer Lett 2009, 282:14-24.
89. Becker M.A., Hou X., Harrington S.C., et al. IGFBP ratio confers resistance to IGF targeting and correlates with increased invasion and poor outcome in breast tumors. Clin Cancer Res 2012, 18:1808-1817.
90. Javle M.M., Shroff R.T., Varadhachary G.R., et al. Tumor IGF-1 expression as a predictive biomarker for IGF1R-directed therapy in advanced pancreatic cancer (APC). J Clin Oncol 2012, 30. [suppl.; abstr. 4054].
91. Gong Y., Yao E., Shen R., et al. High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507). PLoS One 2009, 4:e7273.
92. Huang F., Greer A., Hurlburt W., et al. The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. Cancer Res 2009, 69:161-170.
93. de Bono J.S., Attard G., Adjei A., et al. Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor. Clin Cancer Res 2007, 13:3611-3616.
94. Browne B.C., Eustace A.J., Kennedy S., et al. Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours. Breast Cancer Res Treat 2012, 136:717-727.
95. Wynes M.E., Asuncion B.R., Dziadziuszko R., Glisson B.S., Wisuba I.I., Hirsch F.R. Insulin-like growth factor (IGF-1R) protein expression (PE) and gene copy number 9GCN) for discrimination of response and outcome to figitumumab in NSCLC. J Clin Oncol 2012, 30. [suppl.; abstr. 7597].
96. Kim J.G., Kang M.J., Yoon Y.K., et al. Heterodimerization of glycosylated insulin-like growth factor-1 receptors and insulin receptors in cancer cells sensitive to anti-IGF1R antibody. PLoS One 2012, 7:e33322.
97. Aleksic T., Chitnis M.M., Perestenko O.V., et al. Type 1 insulin-like growth factor receptor translocates to the nucleus of human tumor cells. Cancer Res 2010, 70:6412-6419.
98. Sehat B., Tofigh A., Lin Y., et al. SUMOylation mediates the nuclear translocation and signaling of the IGF-1 receptor. Sci Signal 2010, 3:ra10.
99. Sarfstein R., Pasmanik-Chor M., Yeheskel A., et al. Insulin-like growth factor-I receptor (IGF-IR) translocates to nucleus and autoregulates IGF-IR gene expression in breast cancer cells. J Biol Chem 2012, 287:2766-2776.
100. Bodzin A.S., Wei Z., Hurtt R., et al. Gefitinib resistance in HCC mahlavu cells: upregulation of CD133 expression, activation of IGF-1R signaling pathway, and enhancement of IGF-1R nuclear translocation. J Cell Physiol 2012, 227:2947-2952.
101. Asmane I., Watkin E., Alberti L., et al. Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas. Eur J Cancer 2012, 48:3027-3035.
102. Zhang H., Sachdev D., Wang C., et al. Detection and downregulation of type I IGF receptor expression by antibody-conjugated quantum dots in breast cancer cells. Breast Cancer Res Treat 2009, 114:277-285.
103. Chitnis M.M., Yuen J.S., Protheroe A.S., et al. The type 1 insulin-like growth factor receptor pathway. Clin Cancer Res 2008, 14:6364-6370.
104. Potratz J.C., Saunders D.N., Wai D.H., et al. Synthetic lethality screens reveal RPS6 and MST1R as modifiers of insulin-like growth factor-1 receptor inhibitor activity in childhood sarcomas. Cancer Res 2010, 70:8770-8781.
105. Pitts T.M., Tan A.C., Kulikowski G.N., et al. Development of an integrated genomic classifier for a novel agent in colorectal cancer: approach to individualized therapy in early development. Clin Cancer Res 2010, 16:3193-3204.
106. Isebaert S.F., Swinnen J.V., McBride W.H., et al. Insulin-like growth factor-type 1 receptor inhibitor NVP-AEW541 enhances radiosensitivity of PTEN wild-type but not PTEN-deficient human prostate cancer cells. Int J Radiat Oncol Biol Phys 2011, 81:239-247.
107. Chitnis M.M., Lodhia K.A., Aleksic T., et al. IGF-1R inhibition enhances radiosensitivity and delays double-strand break repair by both non-homologous end-joining and homologous recombination. Oncogene 2013, [epub Nov 4].
108. Yeh J., Litz J., Hauck P., et al. Selective inhibition of SCLC growth by the A12 anti-IGF-1R monoclonal antibody correlates with inhibition of akt. Lung Cancer 2008, 60:166-174.
109. Bao X.H., Takaoka M., Hao H.F., et al. Esophageal cancer exhibits resistance to a novel IGF-1R inhibitor NVP-AEW541 with maintained RAS-MAPK activity. Anticancer Res 2012, 32:2827-2834.
110. Flanigan S.A., Pitts T.M., Newton T.P., et al. Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models. Clin Cancer Res 2013, 19:6219-6229.
111. Zinn R.L., Gardner E.E., Marchionni L., et al. ERK phosphorylation is predictive of resistance to IGF-1R inhibition in small cell lung cancer. Mol Cancer Ther 2013, 12:1131-1139.
112. Sathyanarayanan S., Ayers M., Cunningham D., et al. Activity of the anti-IGF-1R antibody dalotuzumab (MK-0646) in KRAS-mutant colorectal cancer: preclinical and clinical data. J Clin Oncol 2012, 30. [suppl.; abstr. 3587].
113. Kim W.Y., Prudkin L., Feng L., et al. Epidermal growth factor receptor and K-Ras mutations and resistance of lung cancer to insulin-like growth factor 1 receptor tyrosine kinase inhibitors. Cancer 2012, 118:3993-4003.
114. Cohn A.L., Tabernero J., Maurel J., et al. A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer. Ann Oncol 2013, 24:1777-1785.
115. Molina-Arcas M., Hancock D.C., Sheridan C., et al. Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3 kinase in KRAS-mutant lung cancer. Cancer Discov 2013, 3:548-563.
116. Creighton C.J., Casa A., Lazard Z., et al. Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. J Clin Oncol 2008, 26:4078-4085.
117. Litzenburger B.C., Creighton C.J., Tsimelzon A., et al. High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy. Clin Cancer Res 2011, 17:2314-2327.
118. Garofalo C., Mancarella C., Grilli A., et al. Identification of common and distinctive mechanisms of resistance to different anti-IGF-IR agents in Ewing's sarcoma. Mol Endocrinol 2012, 26:1603-1616.
119. Kim E.S., Herbst R.S., Wistuba I.I., et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov 2011, 1:44-53.
120. Yee D., Haddad T., Albain K., et al. Adaptive trials in the neoadjuvant setting: a model to safely tailor care while accelerating drug development. J Clin Oncol 2012, 30:4584-4586. [author reply 4588-9].
121. DeMichele A., Berry D.A., Zujewski J., et al. Developing safety criteria for introducing new agents into neoadjuvant trials. Clin Cancer Res 2013, 19:2817-2823.
122. Wilson T.R., Fridlyand J., Yan Y., et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012, 487:505-509.
123. Belfiore A., Frasca F., Pandini G., et al. Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev 2009, 30:586-623.
124. Ulanet D.B., Ludwig D.L., Kahn C.R., et al. Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy. Proc Natl Acad Sci USA 2010, 107:10791-10798.
125. Bid H.K., Zhan J., Phelps D.A., et al. Potent inhibition of angiogenesis by the IGF-1 receptor-targeting antibody SCH717454 is reversed by IGF-2. Mol Cancer Ther 2012, 11:649-659.
126. Fagan D.H., Uselman R.R., Sachdev D., et al. Acquired resistance to tamoxifen is associated with loss of the type I insulin-like growth factor receptor: implications for breast cancer treatment. Cancer Res 2012, 72:3372-3380.
127. Weroha S.J., Haluska P. The insulin-like growth factor system in cancer. Endocrinol Metab Clin North Am 2012, 41:335-350. [vi].
128. Harrington S.C., Weroha S.J., Reynolds C., et al. Quantifying insulin receptor isoform expression in FFPE breast tumors. Growth Horm IGF Res 2012, 22:108-115.
129. Buck E., Gokhale P.C., Koujak S., et al. Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer. Mol Cancer Ther 2010, 9:2652-2664.
130. Sharma S.V., Lee D.Y., Li B., et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010, 141:69-80.
131. Thariat J., Bensadoun R.J., Etienne-Grimaldi M.C., et al. Contrasted outcomes to gefitinib on tumoral IGF1R expression in head and neck cancer patients receiving postoperative chemoradiation (GORTEC trial 2004-02). Clin Cancer Res 2012, 18:5123-5133.
132. Gallardo A., Lerma E., Escuin D., et al. Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas. Br J Cancer 2012, 106:1367-1373.
133. Huang F., Hurlburt W., Greer A., et al. Differential mechanisms of acquired resistance to insulin-like growth factor-i receptor antibody therapy or to a small-molecule inhibitor, BMS-754807, in a human rhabdomyosarcoma model. Cancer Res 2010, 70:7221-7231.
134. Song R.X., Chen Y., Zhang Z., et al. Estrogen utilization of IGF-1-R and EGF-R to signal in breast cancer cells. J Steroid Biochem Mol Biol 2010, 118:219-230.
135. Dayyani F., Parikh N.U., Varkaris A.S., et al. Combined Inhibition of IGF-1R/IR and Src family kinases enhances antitumor effects in prostate cancer by decreasing activated survival pathways. PLoS One 2012, 7:e51189.
136. Shin D.H., Lee H.J., Min H.Y., et al. Combating resistance to anti-IGFR antibody by targeting the integrin beta3-src pathway. J Natl Cancer Inst 2013, 105:1558-1570.
137. Hou X., Huang F., Macedo L.F., et al. Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer. Cancer Res 2011, 71:7597-7607.
138. Haluska P., Carboni J.M., TenEyck C., et al. HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924. Mol Cancer Ther 2008, 7:2589-2598.
139. Buck E., Eyzaguirre A., Rosenfeld-Franklin M., et al. Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors. Cancer Res 2008, 68:8322-8332.
140. Jameson M.J., Taniguchi L.E., Vankoevering K.K., et al. Activation of the insulin-like growth factor-1 receptor alters p27 regulation by the epidermal growth factor receptor in oral squamous carcinoma cells. J Oral Pathol Med 2012, 42:332-338.
141. Bertrand F.E., Steelman L.S., Chappell W.H., et al. Synergy between an IGF-1R antibody and Raf/MEK/ERK and PI3K/Akt/mTOR pathway inhibitors in suppressing IGF-1R-mediated growth in hematopoietic cells. Leukemia 2006, 20:1254-1260.
142. Atzori F., Tabernero J., Cervantes A., et al. A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res 2011, 17:6304-6312.
143. Fox E.M., Kuba M.G., Miller T.W., et al. Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation. Breast Cancer Res 2013, 15:R55.
144. O'Reilly K.E., Rojo F., She Q.B., et al. MTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006, 66:1500-1508.
145. Yuen J.S., Akkaya E., Wang Y., et al. Validation of the type 1 insulin-like growth factor receptor as a therapeutic target in renal cancer. Mol Cancer Ther 2009, 8:1448-1459.
146. Yilmaz E., Byers L.A., Diao L., Giri U., Gudikote J., Fan Y.H., Wang J., et al. Use of proteomic analysis of LKB/1AMPK/mTOR pathways to identify IGF-1R pathway upregulation with LKB 1 loss or mTOR inhibition in NSCLC: implications for targeted combinations. J Clin Oncol 2012, 30. [suppl.; abstr. 10612].
147. Kurmasheva R.T., Dudkin L., Billups C., et al. The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma. Cancer Res 2009, 69:7662-7671.
148. Beltran P.J., Chung Y.A., Moody G., et al. Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma models. J Pharmacol Exp Ther 2011, 337:644-654.
149. Quek R., Wang Q., Morgan J.A., et al. Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors. Clin Cancer Res 2011, 17:871-879.
150. Naing A., Lorusso P., Fu S., et al. Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma. Br J Cancer 2013, 108:826-830.
151. Heilmann A.M., Perera R.M., Ecker V., et al. CDK4/6 and IGF1 receptor inhibitors synergize to Suppress the growth of p16INK4A-deficient pancreatic cancers. Cancer Res 2014, 74:3947-3958.
152. Miller M.L., Molinelli E.J., Nair J.S., et al. Drug synergy screen and network modeling in dedifferentiated liposarcoma identifies CDK4 and IGF1R as synergistic drug targets. Sci Signal 2013, 6:ra85.
153. Fox E.M., Miller T.W., Balko J.M., et al. A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer. Cancer Res 2011, 71:6773-6784.
154. Robertson J.F., Ferrero J.M., Bourgeois H., et al. Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial. Lancet Oncol 2013, 14:228-235.
155. Ryan P.D., Neven P., Blackwell K.L., et al. Figitumumab plus exemestane versus exemestane as first-line treatment of postmenopausal hormone receptor-positive advanced breast cancer: a randomized open-label phase II trial. .Cancer Res 2011, 71. [Abstract P1-17-01].
156. Haluska P., Hou X., Huang F., et al. Complete IGF signaling blockade by the dual-kinase inhibitor, BMS-754807, is sufficient to overcome tamoxifen and letrozole resistance in vitro and in vivo. Cancer Res 2009, 69. [Abstract nr 402].
157. Hartog H., Horlings H.M., van der Vegt B., et al. Divergent effects of insulin-like growth factor-1 receptor expression on prognosis of estrogen receptor positive versus triple negative invasive ductal breast carcinoma. Breast Cancer Res Treat 2011, 129:725-736.
158. Davison Z., de Blacquiere G.E., Westley B.R., et al. Insulin-like growth factor-dependent proliferation and survival of triple-negative breast cancer cells: implications for therapy. Neoplasia 2011, 13:504-515.
159. Plymate S.R., Haugk K., Coleman I., et al. An antibody targeting the type I insulin-like growth factor receptor enhances the castration-induced response in androgen-dependent prostate cancer. Clin Cancer Res 2007, 13:6429-6439.
160. Chi K.N., Gleave M.E., Fazli L., et al. A phase II pharmacodynamic study of preoperative figitumumab in patients with localized prostate cancer. Clin Cancer Res 2012, 18:3407-3413.
161. Dean J.P., Sprenger C.C., Wan J., et al. Response of the insulin-like growth factor (IGF) system to IGF-IR inhibition and androgen deprivation in a neoadjuvant prostate cancer trial: effects of obesity and androgen deprivation. J Clin Endocrinol Metab 2013, 98:E820-E828.
162. Dunn S.E., Hardman R.A., Kari F.W., et al. Insulin-like growth factor 1 (IGF-1) alters drug sensitivity of HBL100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs. Cancer Res 1997, 57:2687-2693.
163. Trojanek J., Ho T., Del Valle L., et al. Role of the insulin-like growth factor I/insulin receptor substrate 1 axis in Rad51 trafficking and DNA repair by homologous recombination. Mol Cell Biol 2003, 23:7510-7524.
164. Turney B.W., Kerr M., Chitnis M.M., et al. Depletion of the type 1 IGF receptor delays repair of radiation-induced DNA double strand breaks. Radiother Oncol 2012, 103:402-409.
165. Harb W.A., Sessa C., Hirte H.W., et al. A phase I study evaluating the combination of OSI-906, a dual inhibitor of insulin growth factor-1 receptor (IGF-1R) and insulin receptor (IR) with weekly paclitaxel (PAC) in patients with advanced solid tumors. J Clin Oncol 2011, 29. [suppl.; abstr. 3099].
166. Molife L.R., Fong P.C., Paccagnella L., et al. The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study. Br J Cancer 2010, 103:332-339.
167. Harb W.A., Sessa C., Hirte H.W., et al. Final results of a phase I study evaluating the combination of linsitinib, a dual inhibitor of insulin-like growth factor-1 receptor (IGF-1R), and insulin receptor (IR) with weekly paclitaxel (PAC) in patients (Pts) with advanced solid tumors. J Clin Oncol 2013, 31. [suppl.; abstr. e13502].
168. Rosen L.S., Puzanov I., Friberg G., et al. Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors. Clin Cancer Res 2012, 18:3414-3427.
169. Ellis P.M., Shepherd F.A., Laurie S.A., et al. NCIC CTG IND.190 phase I trial of dalotuzumab (MK-0646) in combination with cisplatin and etoposide in extensive-stage small-cell lung cancer. J Thorac Oncol 2014, 9:410-413.
170. Okusaka T., Ikeda M., Fukutomi A., et al. Safety, tolerability, pharmacokinetics and antitumor activity of ganitumab, an investigational fully human monoclonal antibody to insulin-like growth factor type 1 receptor, combined with gemcitabine as first-line therapy in patients with metastatic pancreatic cancer: a phase 1b study. Jpn J Clin Oncol 2014, 44:442-447.
171. Anon Retraction. J Clin Oncol 2012, 30:4179.
172. Langer C.J., Novello S., Park K., et al. Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer. J Clin Oncol 2014, 32:2059-2066.
173. Kindler H.L., Richards D.A., Garbo L.E., et al. A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer. Ann Oncol 2012, 23:2834-2842.
174. de Bono J.S., Piulats J.M., Pandha H.S., et al. Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer. Clin Cancer Res 2014, 20:1925-1934.
175. Cohen S.J., Feng Y., Catalano P.J., et al. Randomized phase II study of paclitaxel with or without the anti-IGF-IR antibody cixutumumab (IMC-A12) as second-line treatment for patients with metastatic esophageal or GE junction cancer. J Clin Oncol 2014, 32:5s. [suppl.; abstr. 4020].
176. Zeng X., Sachdev D., Zhang H., et al. Sequencing of type I insulin-like growth factor receptor inhibition affects chemotherapy response in vitro and in vivo. Clin Cancer Res 2009, 15:2840-2849.
177. Zeng X., Zhang H., Oh A., et al. Enhancement of doxorubicin cytotoxicity of human cancer cells by tyrosine kinase inhibition of insulin receptor and type I IGF receptor. Breast Cancer Res Treat 2012, 133:117-126.
178. Riesterer O., Yang Q., Raju U., et al. Combination of anti-IGF-1R antibody A12 and ionizing radiation in upper respiratory tract cancers. Int J Radiat Oncol Biol Phys 2011, 79:1179-1187.